对于成年人来说,AUSTEDO和AUSTEDO XR显著改善了晚期运动障碍症状和日常功能,77%的人报告说话更好,大多数人保持了稳定的心理健康. AUSTEDO and AUSTEDO XR significantly improved tardive dyskinesia symptoms and daily functioning in adults, with 77% reporting better speech and most maintaining stable mental health.

在2025年神经科学教育研究所秋季大会上发表的一项实验研究发现,AUSTEDO和AUSTEDO XR显著改善了成年人的晚期运动障碍 (TD) 症状和日常功能. A real-world study presented at the 2025 Neuroscience Education Institute Fall Congress found that AUSTEDO and AUSTEDO XR significantly improved tardive dyskinesia (TD) symptoms and daily functioning in adults. 在接受3个月治疗的27名病人中,多达77%的病人说说话更好,75%的病人吃得更好,59%的病人在日常活动方面有所改进,大西洋、印度洋、地中海和南海地区平均得分减少-2分9。 Among 27 patients treated for three months, up to 77% reported better speech, 75% improved eating, and 59% saw gains in daily activities, with a mean AIMS score reduction of -2.9. 大多数患者(85%)在使用药物与精神病药物同时使用的同时,保持了稳定或改善的心理健康。 Most patients (85%) maintained stable or improved mental health while using the drugs alongside psychiatric medications. 结果支持AUSTEDO对TD和Huntington的工作效率,强化了以前的临床数据。 Results support AUSTEDO’s effectiveness for TD and Huntington’s chorea, reinforcing prior clinical data.